Please Wait...

Neurogranin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Neurogranin is a post-synaptic protein regulating synaptic plasticity, learning and memory consolidation. Neurogranin is thought to be involved in activity-dependent synaptic plasticity and long-term potentiation through the modulation of calcium-mediated signaling pathways. Because of its abundant and preferential neuronal expression, Neurogranin has been identified as a potential marker of neurodegeneration in large-scale gene arrays,  along with other candidate markers such as VILIP-1 (Laterza et al., 2006). Several studies have shown that CSF Neurogranin levels are increased in AD, even at the early clinical stages, and could predict cognitive deterioration (Janelidze et al., 2015; Portelius et al., 2015; Sun et al., 2016; Thorsell et al., 2010).

Bioclinica Lab employs a manual sandwich immunoassay designed for the measurement of Neurogranin in human cerebrospinal fluid.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (2 days ago)
RT @isciencebox: Draft and Final FDA Guidances Detail Development of New Drugs for Neurological Disorders @RAPSorg https://t.co/cAewLypUY7
bioclinica (2 days ago)
RT @RAPSorg: Final @US_FDA Rule Requires Medical Device Trials Outside US to Conform to GCP | #Regulatory Focus https://t.co/jgwaqxfiXl #FD…
bioclinica (2 days ago)
Congrats @bioclinica on @Clin_Info_News Best Practices Award 4 "Transformational Med. Imaging in #ClinicalTrials. '… https://t.co/NxauNywq23
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen